The occurrence and development of tumor are closely related to the imbalance of apoptosis and proliferation regulation. Survivin is a newly discovered member of the apoptosis inhibitory protein (IAP) family with a unique structure. It is widely expressed in embryonic and developmental fetal tissues, with low or no expression in normal terminal differentiated adult tissues, while it is highly expressed in the vast majority of malignant tumor tissues. With the rapid development of molecular biology technology, a significant breakthrough has been made in the molecular mechanism of cell apoptosis. With the discovery that Survivin is involved in regulating two basic processes in cell life, namely inhibiting apoptosis and promoting cell proliferation, and playing a role in cell division and angiogenesis. The high expression of Survivin in malignant tumors indicates its important role in tumor production, apoptosis, and proliferation. The alimentary canal is one of the most common sites of human malignant tumors. In recent years, the incidence rate of alimentary canal tumors has been increasing year by year. Because of the early symptoms being not typical, it is easy to miss diagnosis, and most of them have entered the middle and late stages when diagnosed, which is easy to recur and metastasize, with a high fatality rate and serious harm to human health. Therefore, finding ideal tumor biomarkers for early diagnosis and monitoring prognosis is of great value. This article reviews the research progress of apoptosis inhibitor protein Survivin and its application in esophageal cancer, liver cancer and pancreatic cancer.
Published in | American Journal of Health Research (Volume 11, Issue 3) |
DOI | 10.11648/j.ajhr.20231103.13 |
Page(s) | 84-94 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Apoptosis Suppressor Protein, Survivin, Biological Characteristics, Esophageal Cancer, Liver Cancer, Pancreatic Cancer, Prognosis
[1] | Cheung CH, Huang CC, Tsai FY, et al. Survivin – biology and potential as a therapeutic target in oncology [J]. OncoTargets Ther 2013, 6 (10): 1453-1462. |
[2] | Jacob NK, Cooley JV, Shirai K, et al. Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation [J]. Onco Targets Ther, 2012, 5 (1): 7-20. |
[3] | Ambrosini G Adida C Altieri DC. A novel anti-apoptosis gene Survivin expressed in cancer and lymphoma [J]. Nat Med, 1997, 3 (8): 917-921. |
[4] | Ma XY. Survivin, an important regulator of cell division and apoptosis: a target for new anticancer drugs [J]. Chemistry of life, 2010, 30 (3): 338-344. |
[5] | Silke J, Vince J. IAPs and cell death [J]. Apoptotic and Non-Apoptotic Cell Death, 2017, (403): 95-117. |
[6] | Gu LH, Zhou RX. Research progress of the relationship between apoptosis inhibitor protein Survivin and gastric cancer [J]. Sichuan J Anat, 2009, 17 (4): 19-21. |
[7] | Atlasi Y, Mowla SJ, Ziaee SA. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer [J]. Cancer Detect Prev, 2009, 32 (4): 308-313. |
[8] | Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma [J]. Br J Surg, 2017; 104 (11): 1433–1442. |
[9] | Xu D, Xu LJ. Progress of anti-apoptosis gene survivin in pancreatic cancer [J]. J Med Postgra, 2013, 26 (3): 319-322. |
[10] | Chen KY, He HH, Ke JY, et al. Expression of survivin gene in proliferation and apoptosis of hepatocellular carcinoma cells [J]. Hainan Med J, 2021, 32 (4): 409-412. |
[11] | Van Opdenbosch N, Lamkanfifi M. Caspases in Cell Death, Inflflammation, and Disease [J]. Immunity. 2019. 50 (6): 1352-1364. |
[12] | Meng J, Dang T. The Effect of CCN1 on the expression of Caspase-2 in Esophageal carcinoma cells [J]. Inner Mongolia Med J, 2022, 54 (6): 641-646. |
[13] | Mazumder S, Plesca D, Almasan A. Caspase-3 Activation is a Critical Determinant of Genotoxic Stress-Induced Apoptosis [J]. Methods Mol Biol, 2015, 1219: 13-21. |
[14] | Liu XB. Analysis of the correlation between apoptosis related protein Caspase and male condyloma acuminatum [J]. Chinese Journal of Human Sexuality, 2020, 29 (11): 134-138. |
[15] | Liu D, YU ZX, Zhang HX. Cyanidin-3-o-glucoside inhibits H2O2 Induced apoptosis by Mediating the cascaded reaction of caspase [J]. Acta Nutrimenta Sinica, 2020, 42 (4): 369-373. |
[16] | Lin XR, Qian H, Lv JW, et al. Research progress of Caspases family involved in cell apoptosis of dental pulp during the root Absorption of deciduous teeth [J]. Stomatology, 2022, 42 (2): 180-183. |
[17] | Jiang X, Zang X, Gu XX, et al. Study on the activation of caspase pathway related to the anti-apoptosis effects of cordycepin on PD cells [J]. J Shenyang Phar Univer 2017, 34 (10): 899-904. |
[18] | Yiming Zhang, Hai Huang, Huimin Zhou, et al. Activation of Nuclear Factor kB Pathway and Downstream Targets Survivin and Livin by SHARPIN Contributes to the Progression and Metastasis of Prostate Cancer [J]. Cancer, 2017, 123 (5): 892-893. |
[19] | Shi ZS, Kang MF. Current situation of survivin in the research of colorectal cancer [J]. Modern Oncology, 2011, 19 (10): 2129-2132. |
[20] | O’connor DS, Schechner JS, Adida C, et al. Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells [J]. Am J Pathol, 2000, 156 (2): 393-398. |
[21] | Chen HL, Xie CH, Zhong QJ, et al. Effects of Bevacizumab Combined with Chemotherapy on Serum VEGF and bFGF Levels in Patients with Advanced Non-squamous Non-small Cell Lung Cancer [J]. Drug Evaluation 2022, 19 (16): 996-999. |
[22] | Hou JZ, Zhang JS, HoU ZJ. Research Development of Integrin-Linked Kinase in Gastrointestinal Tumors [J]. Med Reca, 2019, 25 (22): 4444-4448. |
[23] | Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61 (2): 69-90. |
[24] | Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. Cancer J Clin 2018, 68 (6): 394–424. |
[25] | Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, Featuring the Increasing Incidence of Liver Cancer [J]. Cancer, 2016, 122 (9): 1312-1337. |
[26] | Li B, Liu Y, Peng J, et al. Trends of Esophageal Cancer Incidence and Mortality and Its Influencing Factors in China [J]. Risk Management and Healthcare Policy 2021: 14 4809–4821. |
[27] | Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [J]. Cancer Commun (Lond), 2019, 39 (1): 22-26. |
[28] | Cui FF, He XY, YU ch, et al. Change trend and risk factors of the burden of esophageal cancer in Chinese population from 1990 to 2016 [J]. ChinJ Heal Stat, 2021, 38 (1): 87-91, 95. |
[29] | Zhan SD, Huang JX. Progression of Cyclin A, PTEN, Survivin and p27 expression in esophageal cancer [J]. Modern Oncology, 2014, 22 (9): 2245-2248. |
[30] | Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin In esophageal cancer: correlation with the prognosis and response to chemotherapy [J]. Int J Cancer, 2001, 95 (2): 92-95. |
[31] | Cao M, Yie SM, Wu SM, et al. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance [J]. Clin Exp Metastasis, 2009, 26 (7): 751-758. |
[32] | Zeng J‚ Zhou XM. Expression and relationship of Livin and Survivin in esophageal carcinoma [J]. Clin Med, 2008, 28 (10): 104-106. |
[33] | Malhotra U, Zaidi AH, Kosovec JE, et al. Prognostic Value and Targeted Inhibition of Survivin Expression in Esophageal Adenocarcinoma and Cancer-Adjacent Squamous Epithelium [J]. PLoS One, 2013, 8 (11): e78343. |
[34] | Liu Y, Li L, Qi H, Gao Y, Liu S, et al. Survivin 231G. C Polymophisrm and Gastrointestinal Tract Cancer Risk: A Meta-Analysis [J]. PLoS One, 2013, 8 (2): e54081. |
[35] | Zeng YZ, Wei XL, Zhu JL. Combined detection of survivin, VEGF-C and VEGFR-3 expression and their clinical significance in diagnosis and treatment of esophageal [J]. cancer J Diag Pathol, 2018, 25 (2): 118-121. |
[36] | Feng M, Abbie•M, Shi JY, et al. Expression of miR-143, miR-145 and Survivin mRNA in esophageal cancers among Kazaks [J]. Canceration, aberration, mutation, 2020, 32 (1): 29-32. |
[37] | Wang Y, Gao YF, Yang YY, et al. Expression of miR-34a and survivin in esophageal carcinoma and their correlation with pathological characteristics [J]. Journal of Clinical and Experimental Medicine, 2022, 21 (16): 1271-1725. |
[38] | Hu HL, Li HW, Zhu SM, et al. Effects of Survivin on Smad3 and PD-L1 expression in esophageal cancer cells [J]. Occup and Health, 2022, 38 (8): 1040-1045. |
[39] | Shabahaiti Wusiman, Yang Yinyin, Liu Zhiqin, et al. Regulatory effects of Survivin on Tak1 and NF-κB in esophageal carcinoma cells and its effects on cell cycle and apoptosis [J]. Shandong Pharmace, 2023, 63 (1): 6-9. |
[40] | Liang ZY, Hou JS, Zhang L, et al. Correlation between Survivin Acetylation and PCAF Expression in Esophageal Carcinoma and its Clinical Significance [J]. J Clin Res, 2019, 36 (8): 1475-1477. |
[41] | Liang ZY, Zhao BS, Zheng JX, et al. Correlation of acetyl transferase KAT2A and Survivin protein acetylation in esophageal cancer [J]. Chin Clin Onco, 2023, 28 (1): 16-22. |
[42] | Stewart BW, Wild CP. World cancer report 2014. World health organization [M]. 3rd edn. New York: International Agency for Research on Cancer (IARC) Press, 2014: Chapter 1.1. |
[43] | Gao Pengfei, Li Na, Jing Yinjun. Relationship between CT-perfusion imaging parameters with mucin 1, survivinand microvessel density in patients with liver cancer [J]. Onco Prog, 2022, 20 (2): 148-150, 173. |
[44] | Ikeguchi M, Ueda T, Sakatani T, et al. Expression of Survivin Messenger RNA Correlates With Poor Prognosis in Patients With Hepatocellular Carcinoma [J]. Diagn Mol Pathol, 2002, 11 (1): 33-40. |
[45] | Ye CP, Qiu CZ, Huang ZX, et al. relationship beteen Survivinexpresssion and recurrence, prognosis in hepatocellular carcinoma [J]. Chin J Exp Surg, 2006, 23 (7): 829-830. |
[46] | Feng Jingjing, Lei Wei, Yao Ruyong, et al. Study on the Antiproliferation Effect of Targeting of Survivin siRNA Transfection Combined with 5-FU on Liver Cell Line HepG2 [J]. Progress in Modern Biomedi Cine, 2012, 12 (18): 3446-3449. |
[47] | Fang YQ, Bai X, Qi YL, et al. Expression of Survivin in Primary hepatocellular carcinoma and Paracarcinoma tissues apoptosis inhibitor protein [J]. J Jilin University (Medicine Edition), 2013, 39 (1): 47-50. |
[48] | Dang CS, Wang H, Liu DP, et al. Expression of Survivin in hepatocellular carcinoma with different TNM stages and its clinical significance [J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2018, 27 (24): 2627-2629, 2633. |
[49] | Yang Jing‚ Zhong Sen. Progress in the relationship of survivin and hepatocellular carcinoma [J]. Int J Dig Dis‚ 2007, 27 (4): 269-270, 274. |
[50] | Yang L, Ji SF, Zhu ZY, et al Expression and Significance of Survivin and Survivin-ΔEx3 mRNA in Heplatocellular Carcinoma [J]. Cancer Research on Prevention and Treatment, 2013, 40 (12): 1147-1150. |
[51] | Cras A, Politis B, Balitrand N, et al. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer [J]. Clin Cancer Res, 2012, 18 (2): 442-453. |
[52] | Jin Y, Chen J, Feng Z, et al. The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma [J]. Tumor Biol. 2014, 35 (10): 9905-9910. |
[53] | E Ying, Shang De Gao, You Sheng. Effects of matrine combined with cisplatin on tumor growth and expression of caspase-3 and Survivin in tumor growth of transplanted tumor model in nude mice on human hepatocellular carcinoma cell line HepG2 [J]. Journal of Clinical and Experimental Medicine, 2019, 18 (5): 457-460. |
[54] | Du Lianjiang, Li Jingtao, Cui Jie. Caspase-3, DcR3 expression and SNHG12 mRNA level in cancerous tissues in patients with hepatocellular carcinoma [J]. J Prac Hepatol, 2022, 25 (5): 706-709. |
[55] | Rizvi S, Gores G J. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma [J]. Gastroenterology, 2013, 145 (6): 1215-1229. |
[56] | Bridgewater J, Galle P R, Khan S A, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma [J]. J Hepatol, 2014, 60 (6): 1268-1289. |
[57] | Liu Sanguang, Zhang Jiansheng, Lv Haitao. Expression of Survivin protein and mRNA in extrahepatic cholangiocarcinoma [J]. Chin J Exp Surg, 2006 (8): 1018. |
[58] | Qin Xinglei, Xue Huanzhou, Wang Zuoren, et al. Expression of Survivin in extrahepatic bile duct carcinoma and its correlation with prognosis [J]. Chin J Surg, 2009, 47 (24): 1852-1856. |
[59] | Hong Jianchen. Meta-analysis of Survivin protein expression and clinical relationship in cholangiocarcinoma [D]. 2014, graduate thesis of Fujian Medical University. |
[60] | Xu Peng. The correlation of expression of FHIT with Survivin protein, and prognosis in patients with cholangio-carcinoma [D]. 2012, Master dissertation of Anhui Medical University. |
[61] | Guo X, Han JL, Pei Y, et al. Expression and significance of apoptosis suppressor proteins Survivin and Bcl-2 in cholangiocarcinoma [J]. Chinese Remedies & Clinics, 2015, 15 (6): 765-767. |
[62] | Li Yangjun, Zhang Wei. Expression and correlation of Survivin and Caspase-3 in cholangiocarcinoma [J]. Chin Mod Doct, 2016, 54 (11): 13-16. |
[63] | Li Yan, Yao Hongyue, Tian Yuan, et al. Expression of NF-κB and Survivin in cholangiocarcinoma and their relationship with macrophage infiltration [J]. Chin J Gero, 2017, 37 (18): 4570-4571. |
[64] | Liang Yunfei. The role of MIRNA-218 in the pathogenesis of bile duct carcinoma by Survivin [D]. 2018, postgraduate thesis of Hebei Medical University. |
[65] | Wan Yunle, Ding Wei, Zheng Shusen, et al. Expression and significance of Survivin and Ki-67 in primary gallbladder carcinoma [J]. Chin J Expe Surg‚ 2006‚ 23 (8): 919-921. |
[66] | Shen Hanbin, Zheng Qichang. Survivin expression and its relationship with CD44v6 and nm23 gene expression in gallbladder carcinoma [J]. Chin J Gene Surg, 2005, 14 (8): 614-617. |
[67] | Cai Jie, Chen Hongda, Lu Ming, et al. Trend analysis on morbidity and mortality of pancreatic cancer in China 2005-2015 [J]. Chin J Epidemiology, 2021, 42 (5): 794-800. |
[68] | Feng Cheng-cheng, Peng Qing-lan, Jiao Xue-yang, et al. Trends of Pancreatic Cancer Incidence and Mortality in China from 1990 to 2019 [J]. China Cancer, 2022, 31 (5): 321-326. |
[69] | Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors [J]. World J Oncol, 2019, 10 (1): 10-27. |
[70] | Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and isinvolved in theDevelopment of human pancreatic duct cell tumors [J]. Cancer, 2001, 92 (2): 271-278. |
[71] | Wang YL, Liu Y, Zhang JX, et al. The expression of Survivin Gene and the relationship with proliferative activity in pancreatic adenocarcinoma [J]. Chin J Gene Surg‚ 2005, 14 (11): 817-819. |
[72] | Zhang PB, Ding WC, Zhang XZ, et al. Expression and prognostic significance of survivin in pancreatic carcinoma tissue in the elderly patients [J]. Pract Geriatr, 2014, 28 (8): 669-671. |
[73] | Liu BB, Wang WH. Survivin and pancreatic cancer [J]. World J Clin Oncol, 2011, 2 (3): 164-168. |
[74] | Shang Pei-zhong, Wang Jin, Ma, et al. Expression and Clinical Significance of Survivin in Pancreatic Carcinoma Tissues [J]. Med & Pharm J Chin PLA, 2013, 25 (3): 47-49. |
[75] | Sun Guogui, Wang Yadi, Hu Wanning. Expression of survivin in patients with pancreatic cancer: A meta-analysis [J]. Chin Gene Clin, 2012, 28 (4): 435-439. |
[76] | Liu Jinlong, Zhang Xuejun, Yang Shuguang, et al. Meta-analysis: prognostic value of survivin in patients with pancreatic cancer Chinese-German J Clin Oncol June 2014, 13 (6): 273–279. |
[77] | Sun Qiu-jia, Zhuang Yan, Gao Shi-yong. Advances in relation between inhibitor of apoptosis protein and cancer [J]. Journal of Harbin University of Commerce (Natural Sciences Edition), 2015, 31 (1): 9-14. |
[78] | ZAI Hong-yan, YI Xiao-ping, LI Yi-xiong, et al. X-linked inhibitor of apoptosis protein (XIAP) and Survivin suppression on human pancreatic cancer cells Panc-1 proliferation and chemosensitivety [J]. Journal of Peking University (Health Science), 2013, 45 (2): 242-249. |
[79] | Chen Z J. Expression of Ki-67 and Survivin in pancreatic cancer and their clinical significance [J]. Chin J Gero, 2013, 33 (21): 5336-5337. |
[80] | Zhao Su, Cui Weidong, Song Weihua. Expression of survivin and caspase 3 protein in pancreatic cancer tissues and its relationship with clinical features of patients with pancreatic cancer [J]. Onco Prog, 2018, 16 (10): 1275-1277, 1287. |
APA Style
Zhang Shuli, Hou Jianzhang, Li Hongyan, Hou Zhenjiang, Zhang Fengqiao. (2023). Research Progress on Apoptosis Inhibitory Protein Survivin and Its Application in Digestive Tract Tumors. American Journal of Health Research, 11(3), 84-94. https://doi.org/10.11648/j.ajhr.20231103.13
ACS Style
Zhang Shuli; Hou Jianzhang; Li Hongyan; Hou Zhenjiang; Zhang Fengqiao. Research Progress on Apoptosis Inhibitory Protein Survivin and Its Application in Digestive Tract Tumors. Am. J. Health Res. 2023, 11(3), 84-94. doi: 10.11648/j.ajhr.20231103.13
AMA Style
Zhang Shuli, Hou Jianzhang, Li Hongyan, Hou Zhenjiang, Zhang Fengqiao. Research Progress on Apoptosis Inhibitory Protein Survivin and Its Application in Digestive Tract Tumors. Am J Health Res. 2023;11(3):84-94. doi: 10.11648/j.ajhr.20231103.13
@article{10.11648/j.ajhr.20231103.13, author = {Zhang Shuli and Hou Jianzhang and Li Hongyan and Hou Zhenjiang and Zhang Fengqiao}, title = {Research Progress on Apoptosis Inhibitory Protein Survivin and Its Application in Digestive Tract Tumors}, journal = {American Journal of Health Research}, volume = {11}, number = {3}, pages = {84-94}, doi = {10.11648/j.ajhr.20231103.13}, url = {https://doi.org/10.11648/j.ajhr.20231103.13}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20231103.13}, abstract = {The occurrence and development of tumor are closely related to the imbalance of apoptosis and proliferation regulation. Survivin is a newly discovered member of the apoptosis inhibitory protein (IAP) family with a unique structure. It is widely expressed in embryonic and developmental fetal tissues, with low or no expression in normal terminal differentiated adult tissues, while it is highly expressed in the vast majority of malignant tumor tissues. With the rapid development of molecular biology technology, a significant breakthrough has been made in the molecular mechanism of cell apoptosis. With the discovery that Survivin is involved in regulating two basic processes in cell life, namely inhibiting apoptosis and promoting cell proliferation, and playing a role in cell division and angiogenesis. The high expression of Survivin in malignant tumors indicates its important role in tumor production, apoptosis, and proliferation. The alimentary canal is one of the most common sites of human malignant tumors. In recent years, the incidence rate of alimentary canal tumors has been increasing year by year. Because of the early symptoms being not typical, it is easy to miss diagnosis, and most of them have entered the middle and late stages when diagnosed, which is easy to recur and metastasize, with a high fatality rate and serious harm to human health. Therefore, finding ideal tumor biomarkers for early diagnosis and monitoring prognosis is of great value. This article reviews the research progress of apoptosis inhibitor protein Survivin and its application in esophageal cancer, liver cancer and pancreatic cancer.}, year = {2023} }
TY - JOUR T1 - Research Progress on Apoptosis Inhibitory Protein Survivin and Its Application in Digestive Tract Tumors AU - Zhang Shuli AU - Hou Jianzhang AU - Li Hongyan AU - Hou Zhenjiang AU - Zhang Fengqiao Y1 - 2023/06/06 PY - 2023 N1 - https://doi.org/10.11648/j.ajhr.20231103.13 DO - 10.11648/j.ajhr.20231103.13 T2 - American Journal of Health Research JF - American Journal of Health Research JO - American Journal of Health Research SP - 84 EP - 94 PB - Science Publishing Group SN - 2330-8796 UR - https://doi.org/10.11648/j.ajhr.20231103.13 AB - The occurrence and development of tumor are closely related to the imbalance of apoptosis and proliferation regulation. Survivin is a newly discovered member of the apoptosis inhibitory protein (IAP) family with a unique structure. It is widely expressed in embryonic and developmental fetal tissues, with low or no expression in normal terminal differentiated adult tissues, while it is highly expressed in the vast majority of malignant tumor tissues. With the rapid development of molecular biology technology, a significant breakthrough has been made in the molecular mechanism of cell apoptosis. With the discovery that Survivin is involved in regulating two basic processes in cell life, namely inhibiting apoptosis and promoting cell proliferation, and playing a role in cell division and angiogenesis. The high expression of Survivin in malignant tumors indicates its important role in tumor production, apoptosis, and proliferation. The alimentary canal is one of the most common sites of human malignant tumors. In recent years, the incidence rate of alimentary canal tumors has been increasing year by year. Because of the early symptoms being not typical, it is easy to miss diagnosis, and most of them have entered the middle and late stages when diagnosed, which is easy to recur and metastasize, with a high fatality rate and serious harm to human health. Therefore, finding ideal tumor biomarkers for early diagnosis and monitoring prognosis is of great value. This article reviews the research progress of apoptosis inhibitor protein Survivin and its application in esophageal cancer, liver cancer and pancreatic cancer. VL - 11 IS - 3 ER -